Novo Nordisk's Weekly Amycretin Delivers Up to 22% Weight Loss in Study, Stock Soars
Novo Nordisk A/S (NYSE:NVO) released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous administration. The trial investigated the safety, tolerability, pharmacokinetics,
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...
Here are some of the major companies whose stocks moved on the week’s news.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback